HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso" or "the Company") today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS)....
Hence then, the article about akeso reports phase 3 trials show positive results gumokimab il 17 for ankylosing spondylitis and manfidokimab il 4ra for atopic dermatitis achieve primary endpoints was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints )
Also on site :
- Hundreds of flights delayed at O'Hare after pipe burst at air traffic control tower
- Humans&, a ‘human-centric’ AI startup founded by Anthropic, xAI, Google alums, raised $480M seed round
- Karamo Brown Skips 'Queer Eye' Interviews and Says He Felt 'Mentally and Emotionally Abused' for Years